Skip to main content Skip to section menu

A Randomised Investigation of Alternative Ofatumumab-containing regimens in less fit patients with CLL (RIAltO)

Funder: GSK, Napp Pharmaceuticals and Chugai Pharma UK Ltd


Project Summary: Two-arm, open-label, phase III, randomised controlled trial of ofatumumab + chlorambucil (O-Chl) versus ofatumumab + bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia (CLL) who are considered not fit enough for rituximab, fludarabine and cyclophosphamide (R-FC).




Site footer